313 related articles for article (PubMed ID: 26721226)
1. Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
Toussi A; Stewart-Merrill SB; Boorjian SA; Psutka SP; Thompson RH; Frank I; Tollefson MK; Gettman MT; Carlson RE; Rangel LJ; Karnes RJ
J Urol; 2016 Jun; 195(6):1754-9. PubMed ID: 26721226
[TBL] [Abstract][Full Text] [Related]
2. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?
Amling CL; Bergstralh EJ; Blute ML; Slezak JM; Zincke H
J Urol; 2001 Apr; 165(4):1146-51. PubMed ID: 11257657
[TBL] [Abstract][Full Text] [Related]
3. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy.
Mir MC; Li J; Klink JC; Kattan MW; Klein EA; Stephenson AJ
Eur Urol; 2014 Aug; 66(2):204-10. PubMed ID: 24007712
[TBL] [Abstract][Full Text] [Related]
4. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes.
Cookson MS; Aus G; Burnett AL; Canby-Hagino ED; D'Amico AV; Dmochowski RR; Eton DT; Forman JD; Goldenberg SL; Hernandez J; Higano CS; Kraus SR; Moul JW; Tangen C; Thrasher JB; Thompson I
J Urol; 2007 Feb; 177(2):540-5. PubMed ID: 17222629
[TBL] [Abstract][Full Text] [Related]
5. Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?
Sokoll LJ; Zhang Z; Chan DW; Reese AC; Bivalacqua TJ; Partin AW; Walsh PC
J Urol; 2016 Feb; 195(2):330-6. PubMed ID: 26307160
[TBL] [Abstract][Full Text] [Related]
6. Ultrasensitive prostate specific antigen after prostatectomy reliably identifies patients requiring postoperative radiotherapy.
Kang JJ; Reiter RE; Steinberg ML; King CR
J Urol; 2015 May; 193(5):1532-8. PubMed ID: 25463990
[TBL] [Abstract][Full Text] [Related]
7. Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy.
Boorjian SA; Tollefson MK; Thompson RH; Rangel LJ; Bergstralh EJ; Karnes RJ
J Urol; 2012 Nov; 188(5):1761-6. PubMed ID: 22998913
[TBL] [Abstract][Full Text] [Related]
8. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
9. Does Early Prostate Specific Antigen Doubling Time after Radical Prostatectomy, Calculated Prior to Prostate Specific Antigen Recurrence, Correlate with Prostate Cancer Outcomes? A Report from the SEARCH Database Group.
Teeter AE; Griffin K; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Freedland SJ
J Urol; 2018 Mar; 199(3):713-718. PubMed ID: 28870860
[TBL] [Abstract][Full Text] [Related]
10. Low detectable prostate specific antigen after radical prostatectomy--treat or watch?
Koulikov D; Mohler MC; Mehedint DC; Attwood K; Wilding GE; Mohler JL
J Urol; 2014 Nov; 192(5):1390-6. PubMed ID: 24859441
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
Liesenfeld L; Kron M; Gschwend JE; Herkommer K
J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
[TBL] [Abstract][Full Text] [Related]
12. Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen.
Freedland SJ; Sutter ME; Dorey F; Aronson WJ
Urology; 2003 Feb; 61(2):365-9. PubMed ID: 12597949
[TBL] [Abstract][Full Text] [Related]
13. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
15. Determining When to Stop Prostate Specific Antigen Monitoring after Radical Prostatectomy: the Role of Ultrasensitive Prostate Specific Antigen.
Matsumoto K; Komatsuda A; Yanai Y; Niwa N; Kosaka T; Mizuno R; Kikuchi E; Miyajima A; Oya M
J Urol; 2017 Mar; 197(3 Pt 1):655-661. PubMed ID: 27590477
[TBL] [Abstract][Full Text] [Related]
16. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
17. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
19. Prostate Specific Antigen Testing after Radical Prostatectomy-Can We Stop at 20 Years?
Ludwig WW; Feng Z; Trock BJ; Humphreys E; Walsh PC
J Urol; 2018 Jan; 199(1):114-119. PubMed ID: 28818527
[TBL] [Abstract][Full Text] [Related]
20. Biochemical recurrence without PSA progression characterizes a subset of patients after radical prostatectomy. Prostate-specific antigen.
Shinghal R; Yemoto C; McNeal JE; Brooks JD
Urology; 2003 Feb; 61(2):380-5. PubMed ID: 12597952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]